Figure 1
From: Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia
Study design. Phase I: Febuxostat (Feb) 40 mg or benzbromarone (Ben) 50 mg was randomly administered to hypertensive patients with inadequate uric acid control once daily for 3 months. Phase II: Febuxostat 20 mg and benzbromarone 25 mg (feb/ben) were administered. Phase III: Ben 50 mg or Feb 40 mg was administered in a modified crossover manner.
